April 28, 2014 – Sandoz continues to advance its industry-leading biosimilars pipeline that currently has six molecules in the Phase III clinical trial/filing prep phase.As part of the Novartis Q1 announcements, Sandoz announced the following biosimila…
Basel, April 24, 2014 – Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolioVideo of Key product …
Basel, April 24, 2014 – Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolioVideo of Key product …
Acquires GSK oncology products, strengthening Novartis’ leading Oncology business with novel therapies and becomes GSK’s preferred commercialization partner for its oncology pipelineCombines Novartis OTC with GSK’s consumer business in a joint venture,…
Acquires GSK oncology products, strengthening Novartis’ leading Oncology business with novel therapies and becomes GSK’s preferred commercialization partner for its oncology pipelineCombines Novartis OTC with GSK’s consumer business in a joint venture,…
Basel, April 9, 2014 – New leaders to continue to build global scale and innovation power in two of the leading Novartis businessesNovartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014. Mr. George succ…
Princeton, New Jersey, April 1, 2014 – Sandoz today announced the US market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex® Ointment.Calcipotriene and betamethasone dipropi…
Holzkirchen, April 2, 2014 – Sandoz announces today that it is launching in Norway AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).The product was first approved in Denmark o…
Princeton, New Jersey, March 27, 2014 – Sandoz today announced the US launch of lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP, a generic version of PREVPAC®1.This product is indicated for the eradication of H. pylor…
Munich, Germany, March 27, 2014 – Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novart…